Revolution Medicines (RVMD) Cash from Operations (2019 - 2026)
Revolution Medicines' quarterly Cash from Operations came in at 354165000.0 in Q1 2026, down 82.15% year-on-year from 1984211836.19 in Q1 2025, and down 29.15% quarter-over-quarter from 274238000.0 in Q4 2025.
Revolution Medicines has reported Cash from Operations for 8 years, with the latest figure at 354165000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 82.15% year-over-year to 354165000.0; the trailing twelve-month figure through Mar 2026 stood at 1057471000.0 (down 78.83% YoY), and the FY2025 full-year result was 897741000.0, down 61.05% from the prior year.
- Cash from Operations for Q1 2026 stood at 354165000.0, down from 274238000.0 in the prior quarter.
- The five-year high for Cash from Operations was 51737000.0 in Q3 2022, with the low at 354165000.0 in Q1 2026.
- Average Cash from Operations over 5 years is 140253823.53, with a median of 128167000.0 recorded in 2024.
- Year-over-year, Cash from Operations decreased 13.11% in 2023 and slumped 157.34% in 2024.
- Tracing RVMD's Cash from Operations over 5 years: stood at 61788000.0 in 2022, then slumped by 95.12% to 120563000.0 in 2023, then fell by 14.7% to 138290000.0 in 2024, then tumbled by 98.31% to 274238000.0 in 2025, then fell by 29.15% to 354165000.0 in 2026.
- The last three Cash from Operations figures came in at 354165000.0 (Q1 2026), 274238000.0 (Q4 2025), and 207311000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | -354.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -354.17 Mn |
| Mar 31, 2026 | -354.17 Mn |
| Dec 31, 2025 | -274.24 Mn |
| Dec 31, 2025 | -274.24 Mn |
| Sep 30, 2025 | -207.31 Mn |
| Sep 30, 2025 | -207.31 Mn |
| Jun 30, 2025 | -221.76 Mn |
| Jun 30, 2025 | -221.76 Mn |
| Mar 31, 2025 | -194.44 Mn |
| Mar 31, 2025 | -194.44 Mn |
| Dec 31, 2024 | -138.29 Mn |
| Dec 31, 2024 | -138.29 Mn |
| Sep 30, 2024 | -130.42 Mn |
| Sep 30, 2024 | -130.42 Mn |
| Jun 30, 2024 | -128.17 Mn |
| Jun 30, 2024 | -128.17 Mn |
| Mar 31, 2024 | -160.56 Mn |
| Mar 31, 2024 | -160.56 Mn |
| Dec 31, 2023 | -120.56 Mn |
| Dec 31, 2023 | -120.56 Mn |
| Sep 30, 2023 | -100.50 Mn |
| Sep 30, 2023 | -100.50 Mn |
| Jun 30, 2023 | -67.12 Mn |
| Jun 30, 2023 | -67.12 Mn |
| Mar 31, 2023 | -62.39 Mn |
| Mar 31, 2023 | -62.39 Mn |
| Dec 31, 2022 | -61.79 Mn |
| Dec 31, 2022 | -61.79 Mn |
| Sep 30, 2022 | -51.74 Mn |
| Sep 30, 2022 | -51.74 Mn |
| Jun 30, 2022 | -55.72 Mn |
| Jun 30, 2022 | -55.72 Mn |
| Mar 31, 2022 | -55.16 Mn |
| Mar 31, 2022 | -55.16 Mn |
| Dec 31, 2021 | -39.27 Mn |
| Dec 31, 2021 | -39.27 Mn |
| Sep 30, 2021 | -36.59 Mn |
| Sep 30, 2021 | -36.59 Mn |
| Jun 30, 2021 | -34.08 Mn |
| Jun 30, 2021 | -34.08 Mn |
| Mar 31, 2021 | -37.25 Mn |
| Mar 31, 2021 | -37.25 Mn |
| Dec 31, 2020 | -25.03 Mn |
| Dec 31, 2020 | -25.03 Mn |
| Sep 30, 2020 | -27.02 Mn |
| Sep 30, 2020 | -27.02 Mn |
| Jun 30, 2020 | -19.99 Mn |
| Jun 30, 2020 | -19.99 Mn |
| Mar 31, 2020 | -28.02 Mn |
| Mar 31, 2020 | -28.02 Mn |
| Dec 31, 2019 | -11.65 Mn |
| Dec 31, 2019 | -11.65 Mn |
| Sep 30, 2019 | -13.86 Mn |
| Sep 30, 2019 | -13.86 Mn |
| Jun 30, 2019 | -11.50 Mn |
| Jun 30, 2019 | -11.50 Mn |
| Mar 31, 2019 | -12.61 Mn |
| Mar 31, 2019 | -12.61 Mn |